A detailed history of Xtx Topco LTD transactions in Allovir, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 46,460 shares of ALVR stock, worth $34,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,460
Previous 54,815 15.24%
Holding current value
$34,380
Previous $37,000 5.41%
% of portfolio
0.0%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.64 - $0.78 $5,347 - $6,516
-8,355 Reduced 15.24%
46,460 $35,000
Q4 2023

Feb 13, 2024

SELL
$0.68 - $2.39 $19,879 - $69,869
-29,234 Reduced 34.78%
54,815 $37,000
Q3 2023

Nov 13, 2023

BUY
$2.15 - $3.64 $180,705 - $305,938
84,049 New
84,049 $180,000
Q1 2023

May 12, 2023

SELL
$3.94 - $7.05 $133,617 - $239,086
-33,913 Reduced 63.48%
19,509 $76,000
Q4 2022

Feb 14, 2023

BUY
$4.7 - $9.98 $175,794 - $373,281
37,403 Added 233.49%
53,422 $274,000
Q3 2022

Nov 14, 2022

BUY
$4.13 - $8.79 $13,228 - $28,154
3,203 Added 24.99%
16,019 $126,000
Q2 2022

Aug 15, 2022

BUY
$3.26 - $7.06 $41,780 - $90,480
12,816 New
12,816 $50,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $68.9M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.